News
The company expects to make the updated Spikevax available to U.S. patients in time for the 2025-26 respiratory virus season.
The FDA has given full approval to Moderna's COVID-19 shot, Spikevax, allowing it to be used in children 6 months to 11 years old, with some limits on who can get it.
The U.S. Food and Drug Administration has granted full approval for Moderna's COVID-19 vaccine, Spikevax, in children aged 6 months through 11 years who are at an increased risk of the disease ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results